This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Fibrillex for amyloidosis – secondary

Fibrillex (NC-503, Eprodisate disodium, sodium1,3-propanedisulfonate, 1,3-propane- disulphonic acid, 1,3-PDS), an orally active amyloid precursor protein antagonist that inhibits amyloid deposition, is in development as a new treatment for amyloid A amyloidosis in patients with underlying chronic inflammation and infection. A pivotal phase II/III randomised, placebo-controlled trial in 183 patients reported that 13.4% more of the treated group had stable or improved kidney function as compared to the placebo group (although this did not meet the primary endpoint). Secondary outcomes indicated that the progression of renal disease is delayed (5-month delay to dialysis). A three-year open-label extension to the trial is ongoing.

Related Posts

There is currently no cure for rheumatoid arthritis. The most common treatment options are steroids to reduce inflammation, medications to reduce pain and inflammation and medications that slow the progression of joint damage from RA. Tocilizumab is already licensed for the treatment of RA as both intravenous and subcutaneous (pre-filled syringe) formulations, however its use, …

Tendoncel is a gel which can be applied directly onto the skin of the elbow. Tendoncel gel contains a mixture of growth factors (a small substance which encourages cells to grow) which help the tendon to repair and heal. A clinical trial of tendoncel in people with severe tennis elbow showed improvements in elbow pain.If …

Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab for the treatment of …

Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab in women with postmenopausal …